New global trial combines GLP-1 drugs and lifestyle to cut cognitive decline
The Alzheimer's Association revealed a new global trial, PROTECT-Cog, to investigate if GLP-1 drugs and lifestyle changes can lower cognitive decline risk in older adults. PROTECT-Cog builds on the US POINTER study, which showed lifestyle programmes gave up to two years of cognitive advantage. Researchers will monitor participants over three years to determine if the integrated strategy is more successful at postponing mild cognitive impairment.
Lost in this story? That's the point of BriefTea.
Open it in the app and tap Learn from this — the Knowledge Galaxy turns the story into a map of everything it assumes you know, one tap at a time. Free, no ads, no paywall.
Get BriefTea on the App Store